当前位置: 首页 > 详情页

Remote ischemic conditioning for the treatment of ischemic moyamoya disease.

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. [2]Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China. [3]Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China. [4]Tangshan Union Medical College Hospital, Tangshan, China. [5]Department of Neurosurgery, Weifang People's Hospital, Wenfang, China. [6]Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA. [7]Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA. [8]Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
出处:
ISSN:

摘要:
This study investigated the safety and efficacy of remote ischemic conditioning (RIC) on ameliorating the sequelae of ischemic moyamoya disease (iMMD). A total of 30 iMMD patients underwent long-term RIC and were followed up at 0.5, 1, and 2 years for clinical outcomes, including frequency of stroke recurrence, Patient Global Impression of Change (PGIC) scale, peak systolic velocities (PSV), and cerebral perfusion. During the whole RIC treatment process, no RIC-related adverse event occurred. Only one of 30 patients suffered a onetime infarction (3.3%), and the ratios of acceptable PGIC were 88.2%, 64.3%, and 92.3% at 0.5, 1, and 2 years follow-up. Kaplan-Meier analysis showed the frequency of stroke recurrence was significantly reduced after RIC (P = .013). The frequency of TIA per week was 1.1 (0.6, 2.8) prior to RIC and 0.1 (0.0, 0.5) post-RIC (P < .01). Compared to baseline, PSV values were significantly reduced after RIC treatment (P = .002 at 0.5, P = .331 at 1, and P = .006 at 2 years). In patients undergoing perfusion studies, 75% obtained improvement on followed-up SPECT and 95% on followed-up PET maps. Remote ischemic conditioning may be beneficial on controlling iMMD-induced ischemic events, relieving symptoms, and improving cerebral perfusion, without incidence of complications in this case series. © 2019 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 神经科学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 神经科学 2 区 药学
JCR分区:
出版当年[2018]版:
Q2 PHARMACOLOGY & PHARMACY Q2 NEUROSCIENCES
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. [2]Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China. [3]Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China.
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院